Monitor clinical trials

Explore recruiting monitor clinical trials.

Recruiting monitor studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Monitor trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

(MOTOR Study) Neuromuscular MOniTOring in pediatric anesthesia. Randomized clinical study

Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Taplucainium Inhalation Powder (NOC-110) in Adults with Refractory or Unexplained Chronic Cough

Belgium, Poland, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

A8081075 - CRIZOTINIB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM PFIZER-SPONSORED CRIZOTINIB CLINICAL STUDIES

Italy

Therapeutic use (Phase IV) EU CTIS Study details

A randomized, placebo-controlled, participant- and investigator-blinded study to evaluate the efficacy in reducing atrial fibrillation burden (AFB) as well as the safety, tolerability, and pharmacokinetics of oral PKN605 in participants with atrial fibrillation

Netherlands, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

C1071015 - ELRANATAMAB POST TRIAL ACCESS: AN OPEN-LABEL, SINGLE-ARM STUDY FOR PARTICIPANTS WITH MULTIPLE MYELOMA CONTINUING FROM PFIZER-SPONSORED ELRANATAMAB CLINICAL STUDIES

France, Spain, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

B9991046 - AVELUMAB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM PFIZER-SPONSORED AVELUMAB CLINICAL STUDIES

Belgium, France, Hungary, Italy, Denmark, Spain +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Monitor trials by city

Monitor in Toronto Monitor in Vancouver Monitor in Montreal Monitor in Calgary Monitor in Edmonton Monitor in Ottawa Monitor in Winnipeg Monitor in Quebec City Monitor in Hamilton Monitor in Kitchener Monitor in London Monitor in Halifax Monitor in New York Monitor in Los Angeles Monitor in Chicago Monitor in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease